

## CERTIFICATE OF MAILING 37 C.F.R. 1.8

hereby certify that this correspondence is being deposited with the U.S. Postal price with sufficient postage as First Class Mail in an envelope addressed to: Commissione for Parents, Washington, DC 20231, on the date below:

April 12, 2001

Date



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Dmitry Gabrilovich et al.

Serial No.: 09/526,320

Filed: March 15, 2000

For: DENDRITIC CELLS TRANSDUCED

WITH A WILD-TYPE SELF GENE

ELICIT POTENT ANTITUMOR IMMUNE

**RESPONSES** 

Group Art Unit: 1636

en L. Highlander

Examiner: Unknown

Atty. Dkt. No.: INRP:074US/SLH

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10025102/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

Steven 1. Highlander

Reg. No. 37,642

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

April 12, 2001



A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE. SUITE 2400

AUSTIN, TEXAS 78701

APR 1 6 2001 6

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

April 12, 2001

TELEPHONE: 512/474-5201

FACSIMILE: 512/536-4598

STEVEN L. HIGHLANDER

PARTNER

INTERNET ADDRESS: SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: 512/536-3184

FILE: INRP:074US

## CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

April 12, 2001

Date

Steven L. Highlander

Commissioner for Patents Washington, DC 20231

RE:

SN 09/526,320 "DENDRITIC CELLS TRANSDUCED WITH A WILD-TYPE SELF GENE ELICIT POTENT ANTITUMOR IMMUNE RESPONSES" - Dmitry Gabrilovich et al.

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (A1-A15, B1-B9 and C1-C33).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10025102/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L. Highlander Reg. No. 37,642

SLH/mar

Encl: as noted